美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Rivastigmine	Film, Transdermal	Modified USP Type VI (cylinder)	50	0. 9 % NaCl at 32º C	500	1, 2, 4, 7, 9 and 12 hours	2009/06/10
Rivastigmine Tartrate	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Rizatriptan Benzoate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Rizatriptan Benzoate	Tablet, (Orally Disintegrating (ODT))			Develop a dissolution method			2024/01/03
Roflumilast	Tablet	II (Paddle)	50	1.0% SDS (sodium dodecyl sulfate) in Phosphate Buffer, pH 6.8	1000	5, 10, 15, 20, 30 and 45	2013/08/15
Rolapitant HCl	Tablet	II (Paddle)	50	0.05 M Sodium Acetate buffer, pH 4.0	900	10, 15, 20, 30 and 45	2016/10/20
Ropinirole HCl	Tablet			Refer to USP			2014/05/15
Ropinirole HCl	Tablet (Extended Release)	II (Paddle)	100	pH 4.0 Citrate-THAM Buffer	500	1, 2, 4, 6, 8, 12, 16, 20 and 24 hours	2009/08/27
Rosuvastatin Calcium	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Rotigotine	Transdermal	Paddle over Disk (Apparatus 5)	50	Phosphate Buffer, pH 4.5 at 32°C	900	15, 30, 60, 90, 120, 150 and 180	2009/07/15
Rucaparib	Tablet	II (Paddle)	75	0.01 N HCl	900	5, 10, 15, 20 and 30	2017/01/19
Rufinamide	Tablet			Refer to USP			2013/08/15
Rufinamide	Suspension			Develop a dissolution method			2023/09/15
Ruxolitinib Phosphate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Sacubitril/Valsartan	Tablet	I (Basket)	75	Phosphate Buffer, pH 6.8[degassed]	900	10, 15, 20, 30 and 45	2019/10/24
Safinamide Mesylate	Tablet	II (Paddle)	100	0.1 N HCL with Sodium Chloride [0.2% (wt/vol) solution], pH 1.2	900	5, 10, 15, 30, 45 and 60	2023/10/06
Sapropterin Dihydrochloride	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Saquinavir Mesylate	Tablet	II (Paddle)	50	Citrate Buffer (pH 3.0)	900	10, 20 , 30 and 45	2007/09/13
Saquinavir Mesylate	Capsule			Refer to USP			2007/09/13
Saxagliptin HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02